CARLSBAD, Calif.--(BUSINESS WIRE)--ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its 11mm Endoluminal Occlusion System (EOS™). Designed for use in the peripheral vasculature, the ArtVentive EOS™ offers immediate and complete vessel occlusion in arterial and venous settings.
“We are excited to introduce the 11mm EOS™ device to the U.S. market. This important new size allows interventional radiologists to treat larger vessels with precision and reliability,” said Dr. Leon Rudakov, President of ArtVentive. “With the introduction of the 11mm EOS™ device, ArtVentive expands its clinical reach treating vessels from 3mm to 11mm in diameter, and meets physician expectations for a device capable of occlusion in these larger diameter vessels.”
“We are proud to be at the forefront of such growing innovation, providing doctors the most advanced technology to effectively treat vascular diseases, stated Jim Graham, ArtVentive Chief Executive Officer. “The EOS™ technology platform serves unmet clinical needs and provides a foundation for future innovation with the potential to address other clinical conditions. We look forward to expanding our market reach within the U.S., as well as internationally.”
About ArtVentive Medical Group, Inc.
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.
The ArtVentive EOS™ is a catheter-based, self-expandable device, which facilitates permanent and immediate occlusion of peripheral vessels. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases.
More information about ArtVentive can be found at www.artventivemedical.com.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.
